Research projects

Alzheimer's disease is incurable, complex and multifactorial. The costs of caring for these patients in the European Union range between 100 and 160 billion per year. Due to the continuous failure of clinical trials aimed at its treatment, the design of novel and more effective therapeutic strategies is required.

In our laboratory we work with mouse models of Alzheimer's disease and have recently developed a viable in vivo reprogramming animal model with the aim of rejuvenating or delaying the progression of the disease.

Our preliminary results obtained in wild-type/control mice indicate that specific intracerebral reprogramming in mice induces facilitation or enhancement of certain cognitive abilities without adverse side effects associated with reprogramming in vivo, such as teratoma formation and death of the specimen (mouse).

The fact that our model has worked in wild-type/control mice, without causing adverse effects and enhancing their cognitive abilities leads us to hypothesize whether this design could reverse the progression of the disease in models of Alzheimer's amyloid and tauopathy and to delve into the results. Molecular mechanisms underlying neurodegenerative diseases associated with aging.

In this sense, our main objectives in this project will be:
1-Induce a controlled reprogramming in vivo at the level of time and of the brain region (Hippocampus) in mouse models of amyloid Alzheimer's (5xFAD).
2-Induce controlled in vivo reprogramming at the time and brain region (hippocampus) level in tauopathy model mice (P301S).
3-Identify the molecular mechanisms underlying the potential improvements and that are associated with reprogramming in vivo in both models.